key: cord-0985719-51ojjoo3 authors: de Cevins, Camille; Luka, Marine; Smith, Nikaïa; Meynier, Sonia; Magérus, Aude; Carbone, Francesco; García-Paredes, Víctor; Barnabei, Laura; Batignes, Maxime; Boullé, Alexandre; Stolzenberg, Marie-Claude; Pérot, Brieuc P.; Charbit, Bruno; Fali, Tinhinane; Pirabarakan, Vithura; Sorin, Boris; Riller, Quentin; Abdessalem, Ghaith; Beretta, Maxime; Grzelak, Ludivine; Goncalves, Pedro; Di Santo, James P.; Mouquet, Hugo; Schwartz, Olivier; Zarhrate, Mohammed; Parisot, Mélanie; Bole-Feysot, Christine; Masson, Cécile; Cagnard, Nicolas; Corneau, Aurélien; Bruneau, Camille; Zhang, Shen-Ying; Casanova, Jean-Laurent; Meunier, Brigitte Bader; Haroche, Julien; Melki, Isabelle; Lorrot, Mathie; Oualha, Mehdi; Moulin, Florence; Bonnet, Damien; Belhadjer, Zahra; Leruez, Marianne; Allali, Slimane; Leguen, Christèle Gras; de Pontual, Loïc; Fischer, Alain; Duffy, Darragh; Rieux-Laucat, Fredéric; Toubiana, Julie; Ménager, Mickaël M. title: A monocyte/dendritic cell molecular signature of SARS-CoV-2 related multisystem inflammatory syndrome in children (MIS-C) with severe myocarditis date: 2021-08-14 journal: Med (N Y) DOI: 10.1016/j.medj.2021.08.002 sha: 82c23c03c5efb3db6de68abae83bfb08aabd0e84 doc_id: 985719 cord_uid: 51ojjoo3 Background SARS-CoV-2 infection in children is generally milder than in adults, yet a proportion of cases result in hyperinflammatory conditions often including myocarditis. Methods To better understand these cases, we applied a multi-parametric approach to the study of blood cells of 56 children hospitalized with suspicion of SARS-CoV-2 infection. Plasma cytokine and chemokine levels and blood cellular composition were measured, alongside gene expression both at the bulk and single cell levels. Findings The most severe forms of multisystem inflammatory syndrome in children related to SARS-CoV-2 (MIS-C), that resulted in myocarditis, were characterized by elevated levels of pro-angiogenesis cytokines and several chemokines. Single-cell transcriptomic analyses identified a unique monocyte/dendritic cell gene signature that correlated with the occurrence of severe myocarditis, characterized by sustained NF-κB activity, TNF-α signaling, associated with decreased gene expression of NF-κB inhibitors. We also found a weak response to type-I and type-II interferons, hyperinflammation and response to oxidative stress related to increased HIF-1α and VEGF signaling. Conclusions These results provide potential for a better understanding of disease pathophysiology. Funding Agence National de la Recherche (Institut Hospitalo-Universitaire Imagine, grant ANR-10-IAHU-01, Recherche Hospitalo-Universitaire, grant ANR-18-RHUS-0010, Laboratoire d’Excellence ‘‘Milieu Intérieur”, grant ANR-10-LABX-69-01, ANR-flash Covid19 “AIROCovid” and “CoVarImm”), Institut National de la Santé et de la Recherche Médicale (INSERM) and the “URGENCE COVID-19” fundraising campaign of Institut Pasteur In adults, critical forms of COVID-19 are typically characterized by severe pneumonia and 104 acute respiratory distress syndrome 1 . In children, symptomatic COVID-19 occurs much less 105 frequently and is milder than in adults for reasons that remain poorly understood 2-6 . 106 However, in regions with high incidence of SARS-CoV-2 infection, some children have 107 presented a postacute hyperinflammatory illness 7 . In these cases, diagnostic evidence of 108 recent SARS-CoV-2 infection has been consistently reported [8] [9] [10] [11] . This condition was named Association 13 . Of note, 21/30 cases had severe myocarditis (i.e. with elevated high-sensitivity 151 cardiac troponin I and/or regional wall motion abnormalities on echocardiography, and 152 clinical signs of circulatory failure requiring intensive care support; MIS-C_MYO (CoV2 + )). 153 Thirteen tested negative for SARS-CoV-2 and fulfilled clinical criteria for complete (n=6) or 154 incomplete (n=7) Kawasaki disease (KD), and were therefore considered to have KD-like 155 illness (KD (CoV2 − ) group) ( Figure S1 , Table S1 ). Clinical and biological characteristics, at 156 time of disease activity and before treatment, or within 24 hours of treatment onset, are 6 decided by the clinician in 16 out of the 43 cases, mostly because of either initial severity, 162 high risk of IVIG unresponsiveness 20 , or IVIG unresponsiveness. They were administered 163 before sampling for some of them (N=1 in MIS-C (CoV2 + ); N=7 in MIS-C_MYO (CoV2 + ); 164 N=4 in KD (CoV2 − )). All cases responded favorably to IVIG alone or in combination with 165 glucocorticosteroids. MIS-C cases had low lymphocyte counts and those with severe 166 myocarditis had abnormally increased neutrophil counts as compared to other groups, along 167 with high levels of C-reactive protein (CRP), procalcitonin (PCT), serum alanine 168 transaminases (ALT) and ferritin (Table S1) . Multi-parametric analyses were performed at a 169 median fever persistence of 9-10 days (Figures 1A, B) healthy donors (CTL) and patients with acute infections (Acute-inf (CoV2 + ) and were also 185 found elevated in the KD (CoV2 − ) group (Figures 2A, B, S2B ). 186 7 Altogether, high inflammatory cytokine levels were detected in both acute infection and 187 postacute inflammatory cases. Even though most patients with postacute hyperinflammation 188 received IVIG and/or corticosteroids before sampling, the strongest inflammatory profile is 189 observed in MIS-C. As both IVIG and corticosteroids are known immune modulators, 190 differences between acute infection and postacute hyperinflammation are unlikely due to the 191 treatments 21,22 . Nevertheless, IVIG treatment could account for the increase of anti-192 inflammatory mediators such as IL-10, IL-1RA and TGF-β1, as previously reported 23-26 . We 193 could not assess the specific effects of IVIG treatment as almost all postacute cases were 194 treated by IVIG before sampling, however the inflammatory profile was much reduced in 195 intensity in MIS-C cases under combined glucocorticosteroid and IVIG treatment, as 196 compared to IVIG alone (Figure 2A) . (Figures 3A, B) , but there was no correlation with 217 clinical data, including treatments, age (Table S1), nor cytokine/chemokine measurements 218 (Figures 2 and S2) . Additional modifications were detected in patients with acute SARS-219 CoV-2 infection (Acute-inf (CoV2 + ) cases), consisting in a decrease of MAIT cells and an 220 excess of naïve and central memory CD4 + T cells (Figures 3A, B , S3 C, D). As the median 221 age is very low in this group (0.2 years, Table S1 ) as compared to other groups, we cannot 222 exclude an age effect. dataset. In patients with acute infection (Acute-inf (CoV2 + ) and Acute-inf (CoV2 − )), the 231 numbers of differentially expressed genes were homogeneously distributed among 232 monocytes/DCs, T and B cells (Figures 4A and S4A) . Pathway enrichment analyses 233 revealed a decrease in oxidative phosphorylation, coupled with an increase of HMGB1 234 signaling, HIF-1 signaling, and hypoxia signaling ( Figure 4B) . Production of nitric oxide 235 was observed in both groups of acute infections, independently of SARS-CoV-2 infection, as 236 compared to healthy controls ( Figure S4B) . These observations suggest a metabolic switch 237 potentially driven by hypoxic conditions. NF-B signaling, VEGF signaling and 238 inflammatory pathways (type-I and type-II IFNs, IL-1, IL-6, and IL-17 signaling pathways) 239 were also found to be overrepresented in both groups of patients ( Figure S4B) . 240 Interestingly, alterations in the same pathways were also identified in all cases of children 241 with SARS-CoV-2-related postacute illnesses (All MIS-C (CoV2 + ): MIS-C_MYO (CoV2 + ) 242 and MIS-C (CoV2 + )). However, in these cases, alterations were mostly restricted to 243 monocytes and DCs (Figures 4A, B) . Comparisons of genes differentially expressed between 244 children with postacute hyperinflammatory illness with or without evidence of SARS-CoV-2 245 , did not reveal significant differences 246 except for type-I and type-II interferon signaling (Figures S4C, D) . 247 The NF-B signaling pathway was identified to be activated in monocytes and DCs of all (Figures S6A, B) . TGF- 284 signaling and VEGF signaling were also found enriched in monocytes and DCs of patients 285 with myocarditis and to a lesser magnitude in B cells (Figures S6A, B) . 286 To summarize, NF-B activation, a decreased expression of NF-B inhibitors, TNF- 287 signaling, together with a hypoxic response to oxidative stress and VEGF signaling, 288 characterize the monocytes and DCs of children with MIS-C and severe myocarditis. prior to sampling, the effect of the treatment is unlikely to explain the differences observed 414 between MIS-C with or without severe myocarditis. Furthermore, IVIG has been described to 415 downregulate rather than upregulate TNF- and NF-B signaling [24] [25] [26] 29 . Of note, an 416 abrogation of type-I IFN responses, following IVIG treatment has been described 50 , although 417 it is unlikely to explain here the differences between both groups of MIS-C. inflammation, TNF- and NF-B signaling, oxidative stress and myocarditis ( Figure S7C) . 432 Interestingly, among these genes, the S100 proteins and the calprotectin complex 433 (S100A8/S100A9) in particular, were previously reported and proposed as biomarkers for the 434 most severe adult form of COVID-19 with acute respiratory syndrome (Figure S7D ) 36 of treatments were discussed throughout the manuscript. Differences in median age between 471 groups exist and were taken into consideration during analyses. All our cellular data were 472 generated from frozen peripheral mononuclear cells, which does not allow a direct 473 assessment of neutrophils and cannot exclude any bias in cell proportions and immune 474 analyses, although all samples were processed using the same methods. A parallel analysis of 475 polymorphonuclear leukocytes will be required. Endothelial and myocardiac cells are at least 476 targets of the disease but may also contribute to the pathophysiology as described above. 477 Also, additional data supporting gene expression findings will be necessary in future studies. 478 Nevertheless, our study provides further in-depth molecular analysis of MIS-C with severe 479 myocarditis. These severe forms were found to be associated with an excessive activation of 480 Figure S1 and Table S1 . Figure 3B . PBMCs represent all clusters; 593 monocytes/cDCs/pDCs, clusters 5, 11, 12, 17, 20, 21, 24; T cells, clusters 0, 1, 2, 4, 6, 7, 10, 594 differentially expressed genes (DEG) from the comparisons performed in A in PBMCs, 599 Left panel, part 1 and right panel part 2. Symbols are used in front to represent pathways of 601 the same functional groups. Pathways with an absolute z-score ≤ 2 or adjusted p-value > 0.05 602 in all conditions were filtered out. Z-score > 2 means that a function is significantly increased 603 (orange) whereas a Z-score < −2 indicates a significantly decreased function (blue). Grey 604 dots indicate non-significant pathways (p > 0.05). C. Heatmap of the activation of NF-B 605 signaling pathway, as predicted by IPA, in Acute-inf (CoV2 + ) and in All MIS-C (MIS-C 606 (CoV2 + ) and MIS-C_MYO (CoV2 + )) compared to controls. Color scale represents the z-score 607 of the prediction. The higher the score, the more activated the NF-B signaling pathway. (Supp1_Metadata) and the workflow is summarized in Figure 1B . -Hyperinflammatory cytokines coupled with decrease in monocytes, cDCs, pDCs in MIS-C -A molecular signature in monocytes can discriminate MIS-C with severe myocarditis -It consists of exacerbated TNF-α signaling linked with decreased NF-κB inhibitors -This is observed in parallel to an absence of type-I and type-II IFN responses Multi-parametric analysis identifies in monocytes and dendritic cells, a molecular signature of the most severe forms of Multisystem Inflammatory Syndrome in Children caused by SARS-CoV-2 infection. Severe myocarditis is characterized by an excess of TNF-α signaling via NF-κB, hypoxic conditions, hyperinflammation in the absence of type-I and type-II interferon responses. Children with SARS-CoV-2 infection were initially thought to have only mild COVID-19 symptoms. However, several weeks into the first wave of SARS-CoV-2 infections, there was a surge of a postacute pathology called Multisystem Inflammatory Syndrome in Children (MIS-C). Authors recruited a cohort of children with suspicion of SARS-CoV-2 infection, and uncovered hyperinflammation, hypoxic conditions, exacerbation of TNF-a signaling via NF-kB and an absence of responses to type-I and type-II IFN secretion in the most severe forms of MIS-C with severe myocarditis. This work led C. de Cevins et al. to identify in monocytes and validate in peripheral blood mononuclear cells, a molecular signature of 25 genes that allows the discrimination of the most severe forms of MIS-C with myocarditis. IFN-γ IL-17A TNF-α IL-10 CCL19 CCL20 IL-6 CXCL10 CSF2 CCL2 TGF-α IL-1RA IL-12P70 TRAIL IL-2 IL-13 IL-15 IL-1A IL-7 CCL11 PD-L1 CX3CL1 IL- BTG1 CD44 NAMPT CEBPB ATP2B1 CEBPD REL LITAF NINJ1 MAP3K8 FOSL2 SQSTM1 BCL2A1 SLC2A3 G0S2 B4GALT1 PLAUR PHLDA1 SMAD3 BIRC2 HBEGF IER3 ETS2 MXD1 NFAT5 NFIL3 GPR183 B4GALT5 ABCA1 IRS2 SLC16A6 SERPINB2 PFKFB3 TIPARP EHD1 BCL3 PER1 KLF9 BHLHE40 VEGFA MAFF CXCL2 CXCL3 SPHK1 SDC4 NR4A3 CCL2 I IFN signature Type-II IFN signature EIF2AK2 TPR KPNB1 DDX58 NUP62 HERC5 UBE2L6 EIF4E3 IFIT1 IFIT3 IFIT2 ISG20 IFITM1 EGR1 RSAD2 IFI35 MX2 XAF1 MX1 STAT2 ISG15 BST2 PSMB8 IFI6 SAMHD1 ADAR IFITM3 IFITM2 OAS1 OAS2 OAS3 IRF3 IRF7 IRF2 IRF5 IRF8 STAT1 GBP2 HLA−F PTPN6 IRF1 HLA−A GBP3 CIITA TRIM14 GBP5 PML CAMK2D JAK2 GBP1 Transmission, Diagnosis, and Treatment of Coronavirus Disease Why is COVID-19 so mild in children? Severe Acute Respiratory Syndrome Coronavirus 946 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review Spread of SARS-CoV-2 in the Icelandic Population CoV-2 rates in adults and children according to the epidemic stages. medRxiv Screening and Severity of Coronavirus Disease 2019 (COVID-19) in 957 Children in Madrid A Proposed Framework and Timeline of the 959 Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and 960 Public Health Implications Multisystem Inflammatory Syndrome in Children 963 Associated with Severe Acute Respiratory Syndrome Coronavirus 2: A Systematic 964 Review COVID-19 and Kawasaki Disease: Novel Virus 967 and Novel Case Kawasaki-like multisystem 970 inflammatory syndrome in children during the covid-19 pandemic Following SARS-CoV-2 Infection: a Controlled Study Clinical Characteristics of 58 Children With 977 a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-978 2 Diagnosis, Treatment, 981 and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health 982 Professionals From the Recognition of a Kawasaki disease shock 985 syndrome Concurrent Respiratory Viruses and Kawasaki Disease Peripheral immunophenotypes in children with 990 multisystem inflammatory syndrome associated with SARS-CoV-2 infection The Immunology of Multisystem 994 Inflammatory Syndrome in Children with COVID-19 Mapping Systemic Inflammation 997 and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) Superantigenic character of an insert unique to SARS-1001 CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation Prediction of intravenous immunoglobulin 1005 unresponsiveness in patients with Kawasaki disease TRRUST v2: an expanded reference database of human and mouse 1008 transcriptional regulatory interactions Review: Intravenous 1010 Immunoglobulin and B Cells: When the Product Regulates the Producer. Arthritis & 1011 Rheumatology Inhibition of maturation 1014 and function of dendritic cells by intravenous immunoglobulin Intravenous 1017 immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear 1018 cells by inducing autophagy IVIG-mediated effector functions in 1020 autoimmune and inflammatory diseases IVIg and LPS Co-stimulation Induces IL-10 Production 1023 by Human Monocytes, Which Is Compromised by an FcγRIIA Disease-Associated Gene 1024 Variant Effect of 1027 intravenous immunoglobulin administration on erythrocyte and leucocyte parameters Immunomodulation of inflammatory 1031 leukocyte markers during intravenous immunoglobulin treatment associated with 1032 clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy Intravenous immunoglobulin therapy: how does 1035 IgG modulate the immune system? Superior Immunomodulatory Effects of 1038 Intravenous Immunoglobulins on Human T-cells and Dendritic Cells: Comparison to Intravenous immunoglobulins suppress T-cell priming 1042 by modulating the bidirectional interaction between dendritic cells and natural killer 1043 cells Tumour 1045 necrosis factor signalling in health and disease Tumor Necrosis Factor: An Apoptosis 1047 JuNKie? Enrichr: interactive and collaborative HTML5 gene list enrichment 1050 analysis tool Enrichr: a comprehensive 1053 gene set enrichment analysis web server 2016 update Elevated Calprotectin and Abnormal 1056 Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 Interleukin-8 (IL-8): 1058 the major neutrophil chemotactic factor in the lung The Role of Interleukin-8 and its Receptors in 1060 Inflammatory Lung Disease Chemokine CXCL1-Mediated Neutrophil Trafficking in the Lung: 1063 Role of CXCR2 Activation Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response 1066 and Disease Severity The Mystery of MIS-C CoV-2 Infection Similarities and differences between the immunopathogenesis of COVID-1072 19-related pediatric inflammatory multisystem syndrome and Kawasaki disease COVID-19, varying genetic resistance to viral disease and immune 1075 tolerance checkpoints Hypoxia Induced NF-κB. Cells 5 NF-κB and HIF crosstalk in immune 1078 responses Autoantibodies against type I IFNs in 1081 patients with life-threatening COVID-19 Impaired type I interferon activity 1084 and inflammatory responses in severe COVID-19 patients Inborn errors of type I IFN immunity in patients 1087 with life-threatening COVID-19 Global absence and targeting of protective 1090 immune states in severe COVID-19 Plasmacytoid dendritic cells, interferon signaling, and FcγR contribute to pathogenesis 1093 and therapeutic response in childhood immune thrombocytopenia Immunopathogenesis of 1096 Myocarditis: The Interplay Between Cardiac Fibroblast Cells, Dendritic Cells, 1097 Macrophages and CD4+T Cells Overexpression of tumor necrosis 1100 factor (TNF) α and TNF α receptor I in human viral myocarditis: clinicopathologic 1101 correlations Tumor Necrosis Factor and Viral Myocarditis: The Fine Line 1103 Between Innate and Inappropriate Immune Responses in the Heart Vascular Endothelial Growth Factor and Its 1106 Relationship to Inflammatory Mediators Cycling 1108 hypoxia promotes a pro-inflammatory phenotype in macrophages via JNK/p65 signaling 1109 pathway Single-Cell RNA Sequencing to Dissect 1112 the Immunological Network of Autoimmune Myocarditis Proinflammatory Cytokines Increase Vascular 1114 Endothelial Growth Factor Expression in Alveolar Epithelial Cells. Mediators of 1115 Inflammation Deep immune profiling of MIS-C 1118 demonstrates marked but transient immune activation compared to adult and pediatric 1119 COVID-19 Dysregulation of immune response in patients with COVID-19 in Wuhan, 1122 China Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in 1125 severe COVID-19 patients Acute Heart Failure in Multisystem 1128 Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic Spectrum of Cardiac 1132 Manifestations in COVID-19 Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus 1135 Disease 2019 (COVID-19) Prevalence and Impact of Myocardial 1138 Injury in Patients Hospitalized With COVID-19 Infection Association of Cardiac 1142 Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases Myocardial Injury in Severe COVID-19 Compared With Non-COVID-19 Acute 1147 Respiratory Distress Syndrome Factors associated with myocardial 1150 SARS-CoV-2 infection, myocarditis, and cardiac inflammation in patients with COVID-19 Coronavirus Infections in Children Including 1153 COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and 1154 Prevention Options in Children Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with 1156 Coronavirus Disease Experts' recommendations for 1160 the management of cardiogenic shock in children. Ann Intensive Care 6, 14. 1161 71 Evaluation of inactivation methods for severe 1164 acute respiratory syndrome coronavirus in noncellular blood products Detection of interferon 1168 alpha protein reveals differential levels and cellular sources in disease A comparison of four 1172 serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples 1173 from different populations Automated Data Cleanup for Mass 1176 Cytometry FlowSOM: Using self-organizing maps for visualization and 1179 interpretation of cytometry data UMAP: Uniform Manifold Approximation and 1181 Projection for Dimension Reduction Comprehensive Integration of Single-1184 Cell Data RNA-Seq Signatures Normalized by mRNA 1187 Abundance Allow Absolute Deconvolution of Human Immune Cell Types Genetic Variation at IFNL4 1191 Influences Extrahepatic Interferon-Stimulated Gene Expression in Chronic HCV Patients. 1192 Graph-based genome 1194 alignment and genotyping with HISAT2 and HISAT-genotype Naive B cells 2 10. CM CD8 11. Intermediary Monocytes 12. Classical Monocytes 2 13. γδ T cells 14. Tregs 15. NK CD56bright 16. MAIT 17. Non−classical Monocytes 18 Macro group Bulk-RNA-SEQ analyses were performed on frozen PBMCs extracted from heparin samples. 854 Courtaboeuf, France). To note, the optional step with the DNase was performed. RNA 856 integrity and concentration were assessed by capillary electrophoresis using Fragment 857Analyzer (Agilent Technologies). RNAseq libraries were prepared starting from 100 ng of 858 total RNA using the Universal Plus mRNA-Seq kit (Nugen) as recommended by the 859 manufacturer. The oriented cDNA produced from the poly-A+ fraction was sequenced on a 860NovaSeq6000 from Illumina (Paired-End reads 100 bases + 100 bases). A total of ~50 861 million of passing-filters paired-end reads was produced per library. 862Paired-end RNA-seq reads were aligned to the human Ensembl genome GRCh38.91 using 863Hisat2 (v2.0.4) 81 and counted using featureCounts from the Subread R package. The raw 864 count matrix was analyzed using DESeq2 (version 1.28.1) 82 . No pre-filtering was applied to 865 the data. Differential expression analysis was performed using the "DESeq" function with 866 default parameters. For visualization and clustering, the data was normalized using the 867 `variant stabilizing transformation` method implemented in the "vst" function. Plots were 868 generated using ggplot2 (version 3.3.2), and pheatmap (version 1.0.12). 869During exploratory analyses, it was noted that the clustering was mainly driven by the sex of 870 the patients. To remove this effect, it was included in the regression formula for DESeq (~sex 871 + groups), and then removed following vst transformation, using "removeBatchEffect" from 872 the "limma" package (version 3.44.3). 873 874 Gene signature analysis 875 To identify genes that could be used as markers of severe myocarditis in the SC-RNA-SEQ 876 dataset, three initial strategies were used, all based on differential expression and selection of 877 the upregulated genes. First, we performed the differential expression between MIS-C_MYO 878 MBOAT7 ASAH1 HBEGF FBP1 TNNT1 SLC44A1 RNF141 ADAP2 SIRPA IRF2BP2 CXXC5 S100A12 CTSB S100A8 SPI1 RNF24 TIMP2 PGD CCDC69 RBM3 SDCBP POLR2L CMTM6 BACH1 HADHB CAPNS1 FOXO3 TOP1MT S100A6 BRI3 TMEM167B RETN FTL FCAR ZYX QSOX1 LGALS1 AATK RUNX1 RPL37 ATP6V1F TMA7 PFDN1 RPL37A CCDC71L CD9 TLNRD1 SRA1 RPL21 PHLDA1 IL1R1 FAM20C ATP6V0B CARD19 ADD3 CTSA PGPEP1 NRIP1 IFNGR2 RIT1 DAZAP2 VAT1 BNIP2 LEPROT RFLNB NAMPT FAM49B C5AR1 GAPDH STK24 GMFB ANPEP SMIM3 ZFAND3 P2RX1 RPL22 VIM PPBP GLUL RPL6 PF4 RAC1 RPL7 CTSD RPS9 GNG5 S100A10 CLU PHC2 ADAM9 MMP24OS LAPTM5 AREG RPS4Y1 ARL8A SLC25A37 SH3BGRL3 SLC6A6 RPL35A GADD45GIP1 ATF4 GSTO1 ALOX5AP CSGALNACT2 CD63 THBD CHMP4B TPD52L2 ASPH NDUFB9 TPST1